Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05742841 · ClinicalTrials.gov registry record · Phase 4
EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)
A Phase 4 study of Lipid Disorder, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05742841 is a Phase 4 study of Lipid Disorder that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05742841, a Phase 4 study of Lipid Disorder, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpatient care (primary care, preventive cardiology, or general cardiology, depending on risk level).
Conditions Studied
Interventions
- DRUG moderate- or high-intensity statin/ rosuvastatin
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2023-07-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05742841
The ClinicalTrials.gov registry entry for NCT05742841 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lipid Disorder appearing as the primary indexed condition, and to 1 intervention - of which moderate- or high-intensity statin/ rosuvastatin is the first listed.
NCT05742841 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05742841 about?
NCT05742841 is a clinical study titled "EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)". The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpat...
What is the current status of trial NCT05742841?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2023-03-08. Estimated completion is 2023-07-15.
What conditions does trial NCT05742841 study?
This clinical trial studies the following conditions: Lipid Disorder.
What interventions are being tested in trial NCT05742841?
The interventions under investigation include: moderate- or high-intensity statin/ rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT05742841?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05742841 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipid Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.